An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide. “We feel that a product like an oral, orforglipron, could serve a significant ...

Novo Nordisk A/S NVO has declared that its GLP-1 drugs for chronic obesity ... Taking a page from Eli Lilly and their LillyDirect online pharmacy, Novo Nordisk launched NovoCare Pharmacy, its ...

outperforming Eli Lilly’s Trulicity in controlling glucose levels and body weight. The phase 3 trial success over Lilly’s Trulicity (dulaglutide), an already-marketed GLP-1 class rival ...

The request follows a similar move by Eli Lilly, which has asked for a ban on ... professionals turning to unapproved versions of GLP-1 drugs as an option for weight loss, saying: "This can ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...